J9341 HCPCS code: Injection, thiotepa (tepylute), 1 mg
J9341 is the HCPCS Level II code for injection, thiotepa (tepylute), 1 mg. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 60 per day on DME suppliers.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2025-07-01 |
| Last action effective | 2025-07-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 60 | Prescribing Information |
| outpatient hospital claims | 60 | Prescribing Information |
| practitioner claims | 60 | Prescribing Information |
What changed for J9341
- July 2025: Code appears in this HCPCS release
- 2025-07-01: J9341 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9341?
J9341 is the HCPCS Level II code for injection, thiotepa (tepylute), 1 mg. Short descriptor: "Inj thiotepa (tepylute) 1 mg".
Does Medicare cover J9341?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
How many units of J9341 can be billed per day?
60 on DME suppliers; 60 on outpatient hospital claims; 60 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9341
- Watch J9341 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9341
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.